105 related articles for article (PubMed ID: 15882169)
41. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
[TBL] [Abstract][Full Text] [Related]
42. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
43. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
44. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
[TBL] [Abstract][Full Text] [Related]
45. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
46. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase.
DeHaan RD; Yazlovitskaya EM; Persons DL
Cancer Chemother Pharmacol; 2001 Nov; 48(5):383-8. PubMed ID: 11761456
[TBL] [Abstract][Full Text] [Related]
47. Allelic expression of p73 in human ovarian cancers.
Codegoni AM; Bertoni F; Patregnani C; Marinetti E; D'Incalci M; Broggini M
Ann Oncol; 1999 Aug; 10(8):949-53. PubMed ID: 10509157
[TBL] [Abstract][Full Text] [Related]
48. Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours.
Fauvet R; Poncelet C; Hugol D; Lavaur A; Feldmann G; Daraï E
Virchows Arch; 2003 Jul; 443(1):38-43. PubMed ID: 12756564
[TBL] [Abstract][Full Text] [Related]
49. Significance of p53 expression in ovarian tumors and its correlation to the morphological differentiation.
Rajesh NG; Rekha K; Krishna B
Indian J Pathol Microbiol; 2007 Apr; 50(2):284-7. PubMed ID: 17883046
[TBL] [Abstract][Full Text] [Related]
50. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
51. [Expression and significance of tumor suppressor gene WAF1 in epithelial ovarian neoplasms].
Cao L; Yang Z; Li X
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):602-4. PubMed ID: 10806783
[TBL] [Abstract][Full Text] [Related]
52. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
53. Relationship between p53-associated proteins and estrogen receptor status in ovarian serous neoplasms.
Cho EY; Choi YL; Chae SW; Sohn JH; Ahn GH
Int J Gynecol Cancer; 2006; 16(3):1000-6. PubMed ID: 16803476
[TBL] [Abstract][Full Text] [Related]
54. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy.
Birner P; Schindl M; Obermair A; Breitenecker G; Oberhuber G
Clin Cancer Res; 2001 Jun; 7(6):1661-8. PubMed ID: 11410504
[TBL] [Abstract][Full Text] [Related]
55. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Sugimoto K; Tai Y; Hando T; Tokuda M
Gynecol Oncol; 2001 Oct; 83(1):56-63. PubMed ID: 11585414
[TBL] [Abstract][Full Text] [Related]
56. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
57. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
[TBL] [Abstract][Full Text] [Related]
58. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.
Candido Dos Reis F; Moreira de Andrade J; Bighetti S
Gynecol Obstet Invest; 2002; 54(3):132-6. PubMed ID: 12571433
[TBL] [Abstract][Full Text] [Related]
59. Volume-corrected mitotic index and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
Miliaras D
Anal Quant Cytol Histol; 1999 Oct; 21(5):425-9. PubMed ID: 10560525
[TBL] [Abstract][Full Text] [Related]
60. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
